TLDR Biotech
The top stories in biotech & pharma, straight to your inbox in only one email. Trusted by 2500+ biotech and pharma professionals.
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | February 1 - 2, 2026
🧬 Novo Nordisk's CagriSema (semaglutide/cagrilintide) tops semaglutide in Ph3 type 2 diabetes trial targeting GLP-1/amylin pathways, Sanofi's venglustat (glucosylceramide synthase inhibitor) hits Ph3 goal in Gaucher disease but misses in Fabry disease, Vaxcyte raises $632.5M public offering - clinical-stage vaccine innovation company, Newsoara + vTv Therapeutics expand partnership for global HPP737 inflammation drug rights with $135M total deal value, Roche + SanegeneBio partner on RNAi programme - $200M upfront + $1.5B milestones
Biotech & Pharma Updates | January 29 - February 1, 2026
🧬 Eli Lilly picks Pennsylvania for fourth US manufacturing site in $27B domestic expansion push, AstraZeneca + CSPC Pharmaceutical partner on obesity drugs - $1.2B upfront + $18.5B biobucks, CDMO Vetter Pharma invests €480M ($574.4M) for new German production facility - targeting 2031 launch with 2,000 jobs, Lexicon Pharmaceuticals announces $94.6M public offering for drug candidate R&D, Sanofi's Rezurock (belumosudil) receives CHMP approval recommendation for chronic graft-versus-host disease treatment
Biotech & Pharma Updates | January 28 - 29, 2026
🧬 AstraZeneca pledges $15B investment in China operations through 2030 for cell therapies and radioconjugates development, Roche wants to be in the “top three” in the obesity market with personalized weight-loss pipeline against Novo Nordisk & Eli Lilly, Agomab Therapeutics aims for $212M IPO to support immunology trials for Crohn's disease candidates, Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development platform, Ascletis reports positive Ph3 safety results for denifanstat (ASC40) FASN inhibitor targeting acne vulgaris, Repertoire Immune Medicines + Eli Lilly collaborate on autoimmune tolerizing therapies with $85M upfront + $1.84B biobucks deal
Biotech & Pharma Updates | January 27 - 28, 2026
🧬 Eikon Therapeutics targets $274M IPO for four clinical-stage oncology candidates, Halozyme Therapeutics acquires Surf Bio for up to $400M to expand subcutaneous drug delivery portfolio, Cellares raises $257M Series D for cell therapy manufacturing platform expansion, Eli Lilly + Seamless Therapeutics partner on hearing loss gene editing platform worth over $1.12B, Antheia raises $24M Series C second close - biosynthetic drug ingredient manufacturing, Tenpoint Therapeutics receives FDA approval for YUVEZZI (carbachol and brimonidine tartrate) combination eye drop treating presbyopia
Biotech & Pharma Updates | January 26 - 27, 2026
🧬 TRexBio raises $50M Series B extension for testing eczema drug TRB-061, Boehringer Ingelheim + Simcere Pharmaceutical partner on IBD bispecific antibody SIM0709 for up to $1.26B total, Roche's CT-388 achieves 22.5% weight loss in Ph2 obesity trial - advancing to Ph3 development, Baseline Therapeutics launches to test GLP-1 drug BT-001 for alcohol use disorder - challenging Eli Lilly, EU and India agree to sweeping free trade pact eliminating 11% tariff on pharmaceutical exports, FDA lifts clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase III trial for ATTR gene editing treatment
Biotech & Pharma Updates | January 25 - 26, 2026
🧬 Sarepta Therapeutics' Elevidys gene therapy shows sustained benefits three years post-treatment in Ph3 Duchenne muscular dystrophy trial, Recipharm debuts new Bengaluru facility for beta-lactam drugs to meet tougher FDA contamination standards, 1stBio Therapeutics raises $22M Series D for HPK1 inhibitor clinical development, Fortitude Biomedicines launches with $13M seed to combine molecular glues with ADCs for next-generation cancer and autoimmune therapies, HanchorBio + WuXi Biologics partner on strategic collaboration for bi- and multi-functional fusion protein development, GSK's Arexvy receives European approval expansion for respiratory syncytial virus prevention in all adults 18 and older
Biotech & Pharma Updates | January 22 - 25, 2026
🧬 Novo Nordisk's oral Wegovy shows very strong launch with 18,410 weekly prescriptions - surpassing other GLP-1s, ST Pharm secures $56M API manufacturing contract with undisclosed US biotech for oligonucleotide treatment, NICE reverses decision to recommend NHS funding for Pfizer's Talzenna with Xtandi for advanced prostate cancer, US House of Representatives passes $1.2T spending bill that could restart FDA's rare pediatric disease priority voucher program, GSK's Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) wins China approval for uncontrolled asthma treatment
Biotech & Pharma Updates | January 21 - 22, 2026
🧬 Samsung Biologics becomes first Korean biopharma to surpass 2 trillion won ($1.36B) profit threshold in 2025, Sandoz eyes $322B biosimilar opportunity as 50+ biologics lose patent protection in golden decade ahead, global pharma manufacturing output surged 9.1% in 2025 due to US tariff threat front-loading activities, Corxel Pharmaceuticals raises $287M Series D1 for obesity pill development and testing, BioMarin veterans launch Mendra with $82M Series A to use AI for rare disease drug development, Corcept Therapeutics' relacorilant shows Ph3 overall survival benefit in platinum-resistant ovarian cancer, Bristol Myers Squibb + Janux Therapeutics partner on tumor-activated cancer drugs, $50M upfront, $850M total deal value
Biotech & Pharma Updates | January 20 - 21, 2026
🧬 J&J targets $100B revenue for 2026, overcoming Stelara patent cliff with oncology growth, Insilico Medicine + Hygtia Therapeutics split rights for preclinical NLRP3 inhibitor - $10M upfront + $56M milestones, Otsuka gains EU approval for Dawnzera (donidalorsen) targeting prekallikrein for hereditary angioedema prevention following Ph3 results, Infinitopes raises $35.1M seed total for oesophageal cancer vaccine trial preparation, Bristol Myers Squibb + Microsoft partner on AI-powered lung cancer detection network, FDA launches PreCheck pilot program to streamline US drug manufacturing facility approval process starting February 1
Biotech & Pharma Updates | January 19 - 20, 2026
🧬 GSK acquires RAPT Therapeutics for $2.2B - targeting food allergy market with ozureprubart antibody, Roche doubles Genentech's North Carolina facility investment to $2B targeting obesity treatments by 2029, Exciva raises $59M Series B for neuropsychiatric treatments + Alzheimer's agitation therapy, Moderna and Merck & Co.'s intismeran autogene plus Keytruda maintains 49% risk reduction in advanced melanoma Ph2 study, Pfizer sell ViiV Healthcare stake to Shionogi in deal worth $2.1 billion
Biotech & Pharma Updates | January 18 - 19, 2026
🧬 Sharp Services invests over €20 million ($23.2M) to expand European injectables packaging capacity amid strong market demand, Cytotheryx raises $60M Series A to develop cell therapy treatments for liver disease, Nxera Pharma reports positive Ph3 results for Quviviq (daridorexant) targeting orexin receptors in insomnia patients, Syngene International + Bristol Myers Squibb extend research collaboration through 2035 covering discovery to commercialization, Astellas Pharma's zolbetuximab receives Scottish Medicines Consortium approval for CLDN18.2-positive gastric cancer treatment
Biotech & Pharma Updates | January 15 - 18, 2026
🧬 Novo Nordisk's oral Wegovy shows strong early prescription uptake - outpacing rival Eli Lilly's Zepbound launch, AgomAb Therapeutics files $100M US IPO - ALK5 inhibitors for inflammatory diseases, ImmunityBio reports promising Ph1 results for CD19 CAR-NK cell therapy in Waldenström macroglobulinemia, AbelZeta + AstraZeneca expand GPC3 CAR-T therapy partnership with $630M China rights acquisition, Sobi's Aspaveli (pegcetacoplan) receives EU approval for C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis